Myasthenia Gravis Therapeutics Market Overview

The Global Myasthenia Gravis Therapeutics Market is expected to grow at a high CAGR of 6% during the forecasting period 2023-2030. Myasthenia gravis is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. Muscles of the eyes, face and swallowing are the most commonly affected muscles in the body. The weakening of these muscles can result in double vision, drooping eyelids, trouble talking, and trouble walking.

Myasthenia Gravis Therapeutics Market Dynamics

Myasthenia Gravis is more common in females than in males, and it usually peaks in onset in men in their 50s or 60s and women in their 20s or 30s. There is no cure for MG, but it can be managed with medications and surgery.

Research on MG is focused on better understanding the autoimmune problems associated with the disease and developing new and more effective treatments. There is also a shift in research from suppressing the immune system to rebalancing it, as researchers are working to develop treatments that target the specific underlying causes of MG.

For More Insights Download Sample

The increasing number of MG cases is expected to continue to drive the growth of the MG therapeutics market in the coming years. This growth is likely to be fueled by the development of new and more effective treatments, as well as the increasing availability of existing treatments to patients in developing countries.

Myasthenia Gravis Therapeutics Market Segment Analysis

By Type

Ocular myasthenia gravisCongenital myasthenia gravisGeneralized myasthenia gravisTransient myasthenia gravisOthers

By Treatment

Cholinesterase inhibitorsImmunosuppressive drugsPlasmapheresis and intravenous immunoglobulinThymectomyOther

By End-user

HospitalClinicsOthers

By Region

North AmericaSouth AmericaEuropeAsia PacificMiddle East and Africa

Major Companies Covered

Alexion Pharmaceutical Inc., Grifols SA,  Avadel Pharmaceuticals plc.,  Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., Shire plc.

About us

DataM Intelligence 4 Market Research is a premier market research and business consulting firm that empowers businesses with accurate, reliable, and real-time market data and insights across a wide range of industries. Established in 2017, we have collaborated with over 750 companies, delivering valuable market intelligence for more than 6000 markets. Our expertise, extensive industry coverage, and robust research methodology have earned us the trust of our clients, making us their go-to partner for market intelligence needs.

At DataM Intelligence, we provide comprehensive, insightful, and actionable market intelligence, helping businesses navigate complex market landscapes and make informed decisions. Our dedicated team of analysts and industry experts possess in-depth knowledge and experience in their respective fields, ensuring the highest levels of accuracy and data integrity. Choose DataM Intelligence for all your market research and business consulting needs and experience the difference our commitment to excellence can make for your business.

Media Contact

Company Name: DataM Intelligence
Contact Person: Sonal Kumari
Email: info@datamintelligence.com
Phone:+1 877 441 4866
Country: United States
Website: https://www.datamintelligence.com/